Genelux (GNLX) Capital Expenditures (2022 - 2026)
Genelux's (GNLX) quarterly Capital Expenditures came in at $921000.0 in Q1 2026, up 2970.0% year-on-year from $30000.0 in Q1 2025, and up 111.24% quarter-over-quarter from $436000.0 in Q4 2025.
Genelux (GNLX) Capital Expenditures (2022 - 2026) Analysis & Trends
Genelux's Capital Expenditures history runs 5 years deep, the most recent figure standing at $921000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 2970.0% year-over-year to $921000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 422.05% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 188.19% from the prior year.
- Capital Expenditures improved to $921000.0 in Q1 2026 per GNLX's latest filing, from $436000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $921000.0 in Q1 2026 and bottomed at $15000.0 in Q1 2022.
- The 5-year median for Capital Expenditures is $171500.0 (2024), against an average of $245714.3.
- Across the five-year window, Capital Expenditures plunged 90.25% in 2024 and jumped 2970.0% in 2026, its largest moves.
- Year by year, Capital Expenditures stood at $15000.0 in 2022, then soared by 1520.0% to $243000.0 in 2023, then tumbled by 60.49% to $96000.0 in 2024, then soared by 354.17% to $436000.0 in 2025, then soared by 111.24% to $921000.0 in 2026.
- Per Business Quant, the three latest GNLX Capital Expenditures figures stand at $921000.0 (Q1 2026), $436000.0 (Q4 2025), and $517000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Genelux | 128.92 Mn | 128.92 Mn | - | 921,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 921,000.00 |
| Mar 31, 2026 | 921,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 243,000.00 |
| Dec 31, 2023 | 243,000.00 |